FIGURE 3.

Analysis of overall survival using the Kaplan‐Meier method based on immunological factors. A, High tumoral LOX‐1 expression group (tumoral LOX‐1‐H) vs low tumoral LOX‐1 expression group (tumoral LOX‐1‐L), P = .574. B, High stromal LOX‐1 expression group (stromal LOX‐1‐H) vs low stromal LOX‐1 expression group (stromal LOX‐1‐L), P = .021. C, High intratumoral CD8⁺ cytotoxic T‐lymphocytes group (CD8⁺ CTL‐H) vs low intratumoral CD8⁺ cytotoxic T‐lymphocytes group (CD8⁺ CTL‐L), P = .013. D, Stromal LOX‐1‐H/CD8⁺ CTL‐H vs stromal LOX‐1‐H/CD8⁺ CTL‐L, P = .017; stromal LOX‐1‐H/CD8⁺ CTL‐H vs stromal LOX‐1‐L/CD8⁺ CTL‐H, P = .021; stromal LOX‐1‐H/CD8⁺ CTL‐H vs stromal LOX‐1‐L/CD8⁺ CTL‐L, P < .001; stromal LOX‐1‐H/CD8⁺ CTL‐L vs stromal LOX‐1‐L/CD8⁺ CTL‐H, P = .902; stromal LOX‐1‐H/CD8⁺ CTL‐L vs stromal LOX‐1‐L/CD8⁺ CTL‐L, P = .204; stromal LOX‐1‐L/CD8⁺ CTL‐H vs stromal LOX‐1‐L/CD8⁺ CTL‐L, P = .203. LOX‐1, lectin‐like oxidized low‐density lipoprotein receptor‐1; CD8⁺ CTL, CD8⁺ cytotoxic T‐lymphocytes